Figure 3.
Antiproliferative activity characterization of ICL-CCIC-0019, CK146 and CK145. (a) Immunoblotting analysis of HDAC1 in HepG2, HCT-116, A549 and Caco-2 cell lines (n = 2); (b) Comparison of growth inhibitory activity among ICL-CCIC-0019, CK146 and CK145 in HCT-116, A549, HepG2 and Caco-2 cells (n = 6, mean ± SD).
